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350INTRODUCTION
Huntington disease (HD) is caused by the expansion of an
unstable CAG repeat in the gene encoding the huntingtin (htt)
protein. This expanded CAG repeat results in a mutant
huntingtin (mhtt) that contains an extended polyglutamine
(polyQ) region within its N-terminal region. Although htt is
ubiquitously expressed, HD neuropathology centres on the
dysfunction and eventual loss of striatal and cortical neurons,
particularly of the GABA-ergic medium spiny neurons within
the striatum (Vonsattel & DiFiglia, 1998). In the 15 years since
the identification of the dynamic mutation responsible for HD,
the discoveries of numerous interacting factors, myriad genes
that are transcriptionally dysregulated, and the deepening
appreciation of aspects of the phenotype that extend beyond
the striatum (such as psychosis, diabetes and weight loss), the
pathogenesis of the disease seems to be getting only more
complex (Petersen & Bjorkqvist, 2006).
Transcriptional dysregulation (with a bias toward the
downregulation of target genes) was discovered early in the
characterization of mhtt effects (Zuccato & Cattaneo, 2009).
The activities of transcription factors and other transcriptional
proteins might be altered by abnormal interactions with
mhtt or by being sequestered into mhtt-containing inclusions
(Benn et al, 2008; Dunah et al, 2002; Steffan et al, 2000; van
Roon-Mom et al, 2002). The diabetes and weight loss that
afflict patients were early clues to metabolic disruption in HD,
and indeed defects in the oxidative phosphorylation pathway
and a diminished concentration of ATP are observed within
regions of the human brain (Brennan et al, 1985; Browne et al,
1997; Jenkins et al, 1993; Seong et al, 2005; Tabrizi et al, 1999).
Additional evidence for the important role of metabolic stress
plays in HD is the ability of the metabolic toxin 3-
nitroproprionic acid (3-NP, a succinate dehydrogenase
(SDH) inhibitor) to mimic several features of the disease
(Beal et al, 1993), and the fact that disruption of c-AMP
response element binding (CREB)-dependent transcription
within the mitochondria augments the toxicity of 3-NP in
neuronal cultures (Lee et al, 2005). More recently, it was
reported that expression of several nuclear-encoded mitochon-
drial proteins (cytochrome c and cytochrome c oxidase
(COXIV)) and their coactivator (peroxisome proliferator-
activated receptor-gamma coactivator 1 alpha, PGC-1a) is
inhibited in multiple HD models as well as post-mortem tissue
from the central nervous system (CNS) of HD patients (Cui
et al, 2006). A coactivator is a protein or protein complex
that increases the likelihood that a gene will be transcribed
without interacting directly with the DNA in a sequence
specific manner. In this context, PGC-1a regulates not only
mitochondrial biogenesis, but also fatty acid oxidation,
triglyceride metabolism and gluconeogenesis (Spiegelman,
2007).
Given this evidence for repressed metabolic gene expres-
sion, several groups have asked whether transcriptional
dysregulation in HD, rather than later-onset metabolic
stressors, might underlie the energy deficit observed in mhtt 2010 EMBO Molecular Medicinecells. Several lines of evidence led us to focus on one particular
candidate transcriptional corepressor: transglutaminase 2
(TG2). First, the transcription factors that control the majority
of the nuclear-encodedmitochondrial proteins (specific protein 1
(Sp1), nuclear respiratory factor 1 (NRF-1) and CREB) contain
glutamine-rich activation domains, and TG2 modifies glutamine
residues in proteins to alter protein–protein interactions
(Tatsukawa et al, 2009). These modifications are carried out
by TG2 catalysing the inter- or intramolecular cross-linking
of a glutamine residue to a lysine residue, or the nucleophilic
attack on the carboxamide of a glutamine residue by amines
(especially polyamines) (Folk and Finlayson, 1977; Lorand &
Conrad, 1984). The transamidating activity of TG2 is induced by
micromolar Ca2þ, which is increased in HD, and is inhibited by
GTP. Second, elevated TG2 activity is observed in HD patients
and in various model systems (Karpuj et al, 1999; Lesort et al,
2000), and levels of biomarkers for proteins modified by TG2 are
increased in the cerebral spinal fluid of HD patients (g-glutamyl
amines such as g-glutamyl e-lysine and several g-glutamyl
polyamines) (Jeitner et al, 2008). Third, homozygous germline
deletion of TG2 extends the lifespan of a mouse model of HD
(Mastroberardino et al, 2002), although the magnitude of this
effect is likely mitigated by compensatory upregulation of other
TG isoforms (Mastroberardino, personal communication). We
hypothesized that endogenous TG2 can modify activation
domains present in transcription factors, reducing their ability
to induce transcription of nuclear-encoded metabolic genes;
alternatively TG2 might polyaminate N-terminal tails of histone
proteins leading to increased electrostatic interaction between
positively charged polyamines and negatively charged DNA, thus
participating in facultative heterochromatin formation. In either
of these models, TG2 hyperactivity, as occurs in HD, would
repress an established adaptive transcriptional pathway and
thereby render vulnerable striatal neurons incapable of respond-
ing to metabolic stress.
A first prediction of both models is that TG2 must be in the
nucleus to mediate heretofore unrecognized effects on
transcriptional silencing; a second prediction is that selective
inhibition of TG2 should normalize transcription in HD
models, and that this should be highly correlated with the
protective effect of TG2 inhibition. Through a series of
experiments in cellular and fly models of HD, we show that
TG2 acts in the nucleus to repress the transcription of two key
metabolic genes, impeding the ability of mhtt-expressing cells
to restore energy homeostasis when confronted with metabolic
stress. TG2 inhibition normalizes these ‘metabolic’ genes
and induces resistance of HD cells to mitochondrial toxins;
unexpectedly this resistance was not associated with the rescue
of abnormal mitochondrial bioenergetics in HD. Rather, TG2
inhibition led to normalization of gene clusters representing
numerous cellular functions. These studies describe a
previously unknown pathophysiological convergence between
TG2 activation and transcriptional dysregulation in HD and
characterize a selective inhibitor of TG2 (ZDON) as a
promising, novel platform for the development of therapeutics
for HD.EMBO Mol Med 2, 349–370 www.embomolmed.org
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TG2 inhibition by either ZDON or genetic deletion increases
mRNA of PGC-1a and cytochrome c
Interest in TG2 as mediator of HD pathophysiology has garnered
increasing support via observations from several labs (all
working in diverse models of HD that range from cells to non-
human primates), that cystamine, a low molecular weight
inhibitor of TG2, is neuroprotective (Karpuj et al, 2002; Fox et al,
2004). Indeed, cystamine alleviates symptoms and increases
lifespan when administered to HD model mice by intraper-
itoneal injection or by dosing their drinking water (Bailey &
Johnson, 2006; Dedeoglu et al, 2002; Van Raamsdonk et al,
2005). However, a strong and recurrent confound in the
interpretation of these studies is that cystamine has numerous
TG2-independent protective effects within cells (Jeitner et al,
2005), including caspase inhibition (Bailey & Johnson, 2006;
Jeitner et al, 2005). Like TG2, caspases have an active site
cysteine, which is essential for their proteolytic functions.
Cystamine possibly acts to inhibit caspases or TG2 by forming a
mixed disulfide within the active site cysteine, thus impairing
their respective functions. Moreover, cystamine, acting via
mechanisms that are still obscure, increases levels of the
versatile antioxidant glutathione, providing another rational
mechanism for its salutary effects in HD (Mao et al, 2006), where
oxidative stress has been well documented (Browne & Beal,
2006). To better examine the biological role of TG2 in HD, we
needed a much more selective TG2 inhibitor (Supporting
Information Table S1). ZDON, a novel peptide-based irrever-
sible TG inhibitor, fulfils this requirement in several respects.
The sequence Z-QVPL (herein referred as ZDON) was
discovered in Zedira GmbH, using a peptide screening approach
of over 60 peptides. The strategy the company used was to
mimic the gluten peptides containing a QLPF or QLPY sequence.
These peptides are highly expressed in celiac patients and they
have been shown to be good substrates for TG2 (TG2 is
implicated in Celiac disease). ZDON mimics the gluten peptide
with a DON (6-diazo-5-oxo-norleucine) core. The active site Cys
residue of TG2 nucleophilically attacks DON, resulting in a
stable thioether adduct. ZDON has an IC50 of 150 nM for
recombinant TG2 (Supporting Information Fig S2). ZDON also
inhibits other TG isoforms (1 and 3), although the IC50 for these
isoforms is higher (not shown). We verified the ability of ZDON
to inhibit semi-purified guinea pig TG2 in a test tube and TG
activity in an established cellular model of HD: immortalized
striatal cells generated from the HdhQ111 knock-in mice
(STHdhQ111 cells bear a full-length htt with an expanded polyQ
tract of 111 CAG repeats; herein after referred to as Q111) using a
recently described dot blot assay (McConoughey et al, 2009).
Control cells were generated from the wild-type littermate mice
expressing full-length wild-type htt (STHdhQ7, herein after
referred to as Q7) (Cattaneo & Conti, 1998; Cui et al, 2006;
Trettel et al, 2000). Using this TG2 activity assay, we found that
50mM ZDON reduced the specific activity of recombinant
guinea pig TG2 by 95% within 30min and by 75% in intact
immortalized striatal neurons in both Q7 and Q111 cell lines
(McConoughey et al, 2009). To confirm the specific actions ofwww.embomolmed.org EMBO Mol Med 2, 349–370ZDON, a structurally similar compound (Zc) that lacks the diazo
group, which determines the reactive properties of ZDON
(Supporting Information Fig S1, reactive group circled), was
found to have no TG2 inhibitory activity in parallel assays.
Additionally, we verified that, unlike the prototypical TG2
inhibitor cystamine, ZDON does not inhibit caspase-3 activity
(Supporting Information Table S1 and Fig S3), nor does it
increase glutathione levels under conditions of cellular cystine
deprivation (Supporting Information Table S1 and Fig S4). These
data, along with the IC50s for inhibition of various TG isoforms in
a test tube, suggest that at the concentration of ZDON (50–
100mM) used in intact cells, we were likely inhibiting other TG
besides TG2. Nevertheless, the effects of ZDON on TG2 are more
selective than previously used inhibitors (e.g. cystamine).
With a selective TG inhibitor in hand, we were able to explore
the possibility that TG2 activity in HD contributes to the
transcriptional dysregulation of metabolic genes. mhtt has been
shown to inhibit the interactions of CREB and transcription
initiation factor TFIID subunit 4 (TAF4) to reduce expression of
genes involved inmetabolic adaptation such as PGC-1a (Cui et al,
2006), a transcriptional coactivator that induces the expression of
a number of genes, including cytochrome c, to compensate for
metabolic stress (Herzig et al, 2000).Moreover, germline deletion
of PGC-1a in mice confers an increased sensitivity to mitochon-
drial toxins and reactive oxygen species (St-Pierre et al, 2006),
and produces a striatal degeneration that is very reminiscent of
HD (Liang &Ward, 2006; Lin et al, 2004).We therefore examined
whether TG2, an enzyme previously thought to influence mostly
cytosolic events in HD, is necessary for repression of PGC-1a and/
or cytochrome c.
Using quantitative real time PCR (RT-PCR), we established
that levels of PGC-1a and cytochrome c were indeed lower in
Q111 immortalized striatal cells than in Q7 cells (by 80 3%
lower for PGC-1a and 40 5% lower for cytochrome c; Fig 1A
and B). In contrast to this, the inhibition of TG2 activity, using
50mMZDON, resulted in increased PGC-1amRNA levels in both
Q7 and Q111 cells, by 4.5-fold and 3-fold (450 and 300%),
respectively (Fig 1A). Q7 and Q111 cells treated with the
structurally similar but inactive analogue of ZDON, Zc, showed
no change in PGC-1a mRNA levels (Fig 1A). Like PGC-1a,
cytochrome cmRNA levels, mildly reduced in Q111 cells relative
to Q7 neurons, were increased threefold (300%) upon TG2
inhibition with ZDON (Fig 1B); as expected, Zc had no effect on
the expression level of cytochrome c (Fig 1B). These data
indicate that TG2 inhibition allows the de-repression of PGC-1a,
a transcriptional coactivator of genes also involved in
mitochondrial biogenesis. As expected from these findings,
TG2 inhibition also derepresses transcription of a gene involved
in mitochondrial biogenesis and function, cytochrome c,
whose transcription can be enhanced by PGC-1a protein.
To demonstrate that restoration of cytochrome c and PGC-1a
transcription by ZDON is due to its TG2 inhibitory function, we
examined cytochrome c and PGC-1a mRNA levels following
TG2 knock down by small interfering RNA (siRNA). Q111 cells
transfected with any one of three unique siRNAs targeted to TG2
(70–80% reduction post-transfection, not shown), resulted in an
increase in both cytochrome c and PGC-1a mRNA levels 2010 EMBO Molecular Medicine 351
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Figure 1. TG2 regulates the expression of PGC-1a and cytochrome c.
A. Basal levels of PGC-1a mRNA are lower in immortalized striatal cells bearing mhtt with 111 CAG repeats (Q111) than in striatal cells bearing WT htt (Q7 cells)
in accordance with prior studies. ZDON treatment increases PGC-1a mRNA levels in both Q7 and Q111 cells, while the catalytically inactive Zc has no effect.
B. Following the reduction in the expression of coactivator, PGC-1a, the nuclear encoded, mitochondrial gene, cytochrome c is diminished in Q111 cells. ZDON
treatment of Q111 cells restores cytochrome c mRNA levels.
C. Three unique siRNA sequences targeted against TG2 (sequences 1–3) augmented cytochrome c and PGC-1a mRNA levels in Q111 cells at 24–48 h post-
transfection relative to no transfection (No Trans) or scrambled siRNA (Control siRNA). The qualitatively similar result between distinct treatment groups
indicates that the effect is target specific and not sequence specific. Each siRNA sequence reduced TG2 mRNA levels by greater than 70% (data not shown).
D. As expected from our ZDON and siRNA studies, mouse embryonic fibroblasts (MEFs) derived from a homozygous (TG2/) mouse contain higher levels of
cytochrome c mRNA than those derived from a WT mouse (TG2R/R MEF).
 Denotes a p< 0.05 and  denotes a p<0.01; # or ## denotes a p< 0.05 or <0.01 when Q111 is compared to Q7.
352(Fig 1C). To further support this finding, cytochrome c levels
were examined in mouse embryo fibroblasts (MEFs) containing
a germline homozygous deletion of TG2 (TG2/ MEF).
Compared to wild-type MEF controls (TG2þ/þ MEF) TG2/
MEFs had an almost fourfold higher cytochrome c mRNA level
(Fig 1D). Importantly, treatment with the TG2 inhibitor, ZDON,
did not further increase cytochrome c mRNA in TG2/ MEFs,
supporting the notion that ZDON modulates cytochrome c
transcription by inhibiting TG2 and not via some off-target effect
(Supporting Information Fig S5). Together, these findings 2010 EMBO Molecular Medicinedemonstrate that TG2 inhibition de-represses transcription of
PGC-1a and cytochrome c, two genes critical for metabolic
adaptation. Moreover, our data suggest a role for TG2 in gene
silencing that does not depend on the presence of mhtt, but that
is heightened by its presence (Fig 1).
Transglutaminase 2 must localize to the nucleus to repress
transcription of PGC-1a and cytochrome c
TG2 is a protein that is distributed in multiple subcellular sites.
While its cytosolic function is the best characterized, itEMBO Mol Med 2, 349–370 www.embomolmed.org
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Figure 2. Nuclear TG2 is necessary to repress the transcription of PGC-1a and cytochrome c.
A. Schematic representation of distinct motifs within the human TG2 sequence heterologously expressed in Q7 and Q111 cells. In order to exclude TG2 from the
nucleus, a nuclear export sequence (NES) was introduced at the N-terminal (NES TG2). Additional point mutations were generated in NLS1 (NN TG2). In red,
three important amino acids of the transamidating domain; in blue, calcium binding sites; in green, guanine–nucleotide binding site.
B. Total lysates from Q7 and Q111 cells transfected with WT TG2, or associated NES and NLS mutants. The level of expression is similar in all the samples. b-Actin
is used as a loading control. The gel is representative of at least three replicates.
C. Immunofluorescence staining shows that WT TG2 is expressed in the cytoplasm and nucleus. NES TG2 is primarily expressed in the cytosol, as predicted.
Biochemical studies verified the reduced nuclear localization of TG2 with NES addition alone or NES addition plus the NLS 1 mutation (see Supporting
Information Fig S6).
D. Overexpression of NES TG2 and NN TG2 increases the mRNA levels of PGC-1a and cytochrome c genes, compared to WT TG2 in mhtt expressing cells.
The results are normalized to WT TG2 expressed in Q7 (n¼ 6); p<0.05 and p<0.01.possesses canonical nuclear localization motifs and is found in
the nucleus (Lesort et al, 1998). To understand if TG2 acts in the
nucleus to regulate transcription of cytochrome c and PGC-1a,
we created two TG2 mutants incapable of being targeted to the
nucleus. TG2 possess two nuclear localization sequences and
interacts with importin a3 (Peng et al, 1999). Amino acid
residues 597–602 in human TG2 are 100% identical to residues
203–209 of the nuclear localization sequence 1 (NLS1) of the
NS1 virus protein. Residues 259–263 are 80% identical to
residues 34–38 of the NLS2 of the NS1 virus protein (Fig 2A).We
mutated one or both of these residues; however, the mutation
proximal to the catalytic core (NLS2) inactivated TG2
transamidating activity (data not shown). In order to establish
the role of subcellular localization in TG’s activities, we felt it
was necessary to preserve TG2 activity in directing TG2 out of
the nucleus. Accordingly, we inserted a nuclear export sequence
from the HIV reverse transcriptase gene (Fischer et al, 1995) towww.embomolmed.org EMBO Mol Med 2, 349–370the N terminal of TG2 (NES TG2-Myc) in addition tomutating its
NLS1 sequence (NN TG2-Myc). We verified that all the variants
generated are expressed at protein levels similar to wild type
(WT) TG2 in Q7 and Q111 cells (Fig 2B) and they all retain their
transamidating activity (Supporting Information Fig S6B). NES
TG2 and NN TG2 are mainly localized in the cytosol as shown in
the representative immunofluorescence micrographs (Fig 2C)
using an antibody to the Myc-Tag to detect only the
heterologous protein. Similar subcellular distribution of the
heterologously expressed mutants (NES TG2-myc and NN TG2-
myc) was observed following subcellular fractionation of
populations of transfected cells and immunoblotting using the
Myc tag antibody (Supporting Information Fig S5A).
As expected, overexpression of NES TG2 and NN TG2 (which
do not target to the nucleus) increased PGC-1a and cytochrome c
expression in Q111 cells (Fig 2D). Of note, NN TG2 was more
effective in upregulating cytochrome c message levels, suggest- 2010 EMBO Molecular Medicine 353
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354ing that the additional NLS mutation may further reduce the
amount of TG2 interacting and or modulating the transcription
of this gene.
Transglutaminase 2 regulates the promoter activity of
cytochrome c
Our studies with the TG2 mutants demonstrated that the
enzymemust be in the nucleus in order to inhibit message levels
of PGC-1a or cytochrome c. Both of these genes have been
implicated in energy homeostasis either by acting as a
coactivator of genes involved in mitochondrial biogenesis and
fatty acid metabolism (PGC-1a) (Puigserver & Spiegelman,
2003) or by acting as an electron carrier in oxidative
phosphorylation (cytochrome c) (Herzig et al, 2000). To further
evaluate themechanism bywhich nuclear TG2 silencesmessage
levels of genes involved in mitochondrial function, we took
advantage of a well-established paradigm for creating energetic
stress (a discrepancy between energy demand and supply) in
cells. Specifically serum starvation (1–3 days) followed by
serum stimulation creates an energetic demand fulfilled, in part,
by increased transcription of the nuclear-encodedmitochondrial
gene cytochrome c (Herzig et al, 2000). We transiently
transfected the Q7 and Q111 immortalized striatal neurons
with a promoter–reporter construct containing 326 bases of the
proximal cytochrome c promoter fused to luciferase (-326-luc, a
generous gift from Dr. Richard Scarpulla) (Fig 3A). Serum
stimulation increased cytochrome c reporter activity over
fivefold in Q7 striatal neurons (532 10% at 48 h starvation)
and, as expected, to a lesser extent (372 13%) in Q111 neurons
(Fig 3B). In parallel experiments we co-transfected the
cytochrome c promoter–reporter construct with cDNA for either
WT TG2 or a catalytically inactive TG2 mutant (C277S) into the
immortalized striatal neurons. Q111 cells were unable to induce
cytochrome c following 48 h serum starvation followed by
restimulation (100% inhibition seen in Fig 3C) while the Q7 cells
showed a significant impairment in cytochrome c induction in
the presence of overexpressed WT TG2 (Fig 3C). Inhibition of
the cytochrome c promoter activity was greatly reduced with co-
transfection of the C277S form of TG2 that has no transamida-
tion activity; these data suggest that transamidation is required
for the predominance of TG2’s abilities to repress transcription.
This model receives further support from the fact that addition
of ZDON, which targets the transamidating activity of
endogenous TG2, resulted in a 250% increase in cytochrome
c promoter activity in Q111 cells grown in normal serum
containingmedia (Fig 3D). A 66 base, inactive fragment (lacking
the CRE and NRF-1 sites, but containing the Sp1 sites) did not
respond to serum stimulation or ZDON treatment (not shown).
Our studies confirmed the necessity of the CRE and NRF-1 sites
to increase cytochrome c promoter activity in response to
energetic stress, and supported the idea that ZDON affects the
transcription of cytochrome c at the promoter level by acting via
the CREB or NRF-1 sites. These results are in agreement with the
hypothesis that TG2 inhibition can enhance cytochrome c and
PGC-1a levels, in part, by promoting and/or regulating their
transcription. 2010 EMBO Molecular MedicineTG2 localizes to the cytochrome c promoter and to
the PGC-1a gene
We showed that TG2 acts in the nucleus to repress transcription
of genes silenced in a HDmodel (Figs 1–3). To establish whether
TG2 localizes to promoters of genes that it can regulate, we
performed chromatin immunoprecipitation assays (ChIPs)
using an antibody specific for TG2. In these assays, Q111 cells
showed almost 10 timesmore TG2 at the cytochrome c promoter
than did Q7 cells (Fig 3E). ZDON treatment dramatically reduced
these levels, to less than those found in Q7 cells (Fig 3E).
Although ZDON also slightly increased the TG2 levels at the
cytochrome c promoter in Q7 cells, this increase was not
statistically significant. These studies are the first to localize
nuclear TG2 to the promoter of an affected gene in HD. To verify
the specificity of our TG2 antibody, we performed parallel ChIPs
in mouse embryo fibroblasts derived from WT and TG2/
animals. As expected, we detected no TG2 at the cytochrome c
promoter in TG2/ fibroblasts (Fig 3E). We also found higher
steady-state levels of cytochrome c message in the TG2/
fibroblasts, consistent with a role for TG2 as a negative regulator
of its expression (Fig 1D).
PGC-1a is a coactivator that can act in concert with CREB,
NRF-1 and Sp1 to enhance cytochrome c expression. Coactiva-
tors act in a number of ways including linking transcription
factors with the basal transcriptional machinery (RNA PolII) to
stimulate transcription. We investigated if TG2 was localized to
the proximal PGC-1a promoter or in coding regions of the gene.
In fact, coding regions of PGC-1a have previously been shown to
be dysregulated by mhtt (Cui et al, 2006). While we could not
find an increase in TG2 occupancy in the proximal promoter of
PGC-1a (near the CRE sites), we observed fivefold greater TG2
occupancy at the boundary region of intron 2 and exon 3 in the
Q111 (Fig 3F) compared to Q7 cells. This increase in TG2
parallels a decrease in RNA PolII occupancy at this site seen in
R6/2 mice (Cui et al, 2006). As expected, ZDON treatment
significantly reduced TG2 occupancy at this site back to Q7
levels. Of note, when TG2mutants (NES TG2 and NN TG2) were
overexpressed in Q111 cells and their ability to bind PGC-1a
gene was compared to that of WT TG2 in Q111 cells, a relevant
decrease in their occupancy was observed (Supporting Informa-
tion Fig S6C).
Altogether, these results show that in the presence of mhtt,
TG2 is localized to the proximal promoter of the cytochrome c
gene and to the coding region of PGC-1a gene and that TG2
inhibition displaces it from chromatin and relieves transcrip-
tional inhibition mediated by mhtt in Q111 cells. These findings
support the hypothesis that nuclear TG2 directly binds to
chromatin and functions as a selective corepressor of transcrip-
tion of genes involved in mitochondrial adaptation in a cellular
model of HD.
To determine whether the effects of ZDON reflect a reversal of
a primary effect of mhtt, we used SH-SY5Y human neuroblas-
toma cells that express an expanded polyQ repeat (Q103) under
the control of a doxycycline inducible promoter in proliferating
cells. The induction of mhtt in human cells decreased the
amount of PGC-1a and cytochrome c mRNA by approximately
50 and 10%, respectively, within 24 h of mhtt inductionEMBO Mol Med 2, 349–370 www.embomolmed.org
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Figure 3. TG2 levels and activity influence the activity of the cytochrome c promoter.
A. A cytochrome c promoter–reporter construct that contains the proximal 326 bp of the cytochrome c promoter (-326-luc), including response elements for
specificity protein 1 (SP1), cAMP (CRE) and nuclear respiratory factor 1 (NRF-1).
B. Q7 and Q111 cells transfected with the -326-luc construct followed by various durations of serum starvation and restimulation (serum re-addition). A more
robust response of cytochrome c promoter activity is induced within Q7 cells (white bars) than Q111 cells (grey bars) relative to control condition (C) of no
serum starvation. These findings indicate that that homeostatic response to energetic stress is repressed in cells expressing mhtt.
C. Co-transfection of a WT TG2 construct with the cytochrome c promoter–reporter greatly inhibited promoter activity in Q7 and Q111 cells compared to cells
that were transfected with GFP and the cytochrome c promoter–reporter. Similarly, a TG2 construct that does not retain cross-linking activity (C277S) lost
the ability to repress the cytochrome c promoter activity in Q7 or Q111 cells. WT and mutant TG2 were expressed at the same protein levels in these
experiments.
D. Inhibition of TG activity by ZDON (50mM for 12 h) increased the cytochrome c -326 promoter–reporter activity in Q111 cells nearly fourfold over non-treated
cells (-326-luc w ZDON). Over-expression of TG2 repressed the promoter activity (-326-luc w TG2).
E, F. Chromatin immunoprecipitation assays showed that more TG2 is located at the cytochrome c promoter (E) and at the PGC-1a gene (F) in non-treated Q111
cells compared to non-treated Q7 cells. TG2 occupancy was sharply decreased in Q111 cells treated with ZDON in both cases. TG2 was found at the
cytochrome c promoter of WT MEFs (TG2þ/þ MEF) but not in MEFs derived from TG2/ cells (TG2/ MEF), confirming the specificity of the TG2 antibody
used for ChIP assays. The data representing each sample is normalized with respect to both IgG immunoprecipitations and input.
p< 0.05 and p< 0.01.
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Figure 4. TG2 inhibition upregulates PGC-1a and cytochrome c transcription in anmhtt-dependant way and it protects immortalized striatal neurons and
human myoblasts against 3-NP-induced mitochondrial toxicity.
A. Induction of mhtt by the addition of doxycycline decreased the amount of PGC-1a mRNA in human neuroblastoma cells. This decrease was reversed by 50mM
ZDON. These results demonstrate that silencing of PGC-1a expression occurs very early following mhtt expression, and is not a distal secondary or tertiary
effect of chronic mhtt expression. Similarly, TG2 inhibition can nullify these proximate effects of mhtt on gene expression.
B. Q7 and Q111 cells were protected from 3-NP toxicity (10 mM for 48 h) by pre-treatment with ZDON (50mM for 12 h). 3-NP inhibits SDH (a TCA
cycle and mitochondrial respiratory chain enzyme) to induce death. Note that in agreement with prior studies, Q111 cells are more vulnerable to 3-NP than
Q7 cells.
C. ZDON (50mM for 2 h) increased the relative amount of PGC-1a and cytochrome c mRNA in both WT human myoblasts and myoblasts derived from HD patients.
In accordance with our model, the ZDON-induced protection is highly correlated with reversal of transcriptional dysregulation in HD.
D. ZDON (50mM for 12 h) protected myoblasts from WT and HD patients against 3-NP toxicity. These findings suggest that ZDON prevents vulnerability induced
by mhtt in a human context.
p< 0.05.
356(Fig 4A). The treatment of these cells with ZDON for 3 h resulted
in the transcriptional upregulation of the expression of PGC-1a
and cytochrome c in accordance with the results previously
described (Fig 1A and B).
Transglutaminase 2 protects against 3-NP toxicity
One line of evidence pointing to the role of metabolic stress in
HD pathogenesis is the ability of the metabolic toxin 3- 2010 EMBO Molecular Medicinenitropropionic acid (3-NP) to mimic several features of the
disease (Beal et al, 1993). We therefore examined whether
ZDON can protect Q7 or Q111 cells against 3-NP toxicity (Bailey
& Johnson, 2006; Borrell-Pages et al, 2006; Dedeoglu et al, 2002;
Mastroberardino et al, 2002; Van Raamsdonk et al, 2005). 3-NP
is an inhibitor of both TCA cycle genes and mitochondrial
oxidative phosphorylation. It is used to model selective
vulnerability of the striatum to metabolic stress in WT animals,EMBO Mol Med 2, 349–370 www.embomolmed.org
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cells (Ruan et al, 2004), an observation that we confirmed
(Fig 4B). Thus, Q7 and Q111 cells were pre-treated with 50mM
ZDON for 12 h and followed by exposing them to 3-NP. After
48 h, the effects of ZDON on viability were evaluated. Pre-
treatment with ZDON almost completely protected both cell
lines, as measured by the calcein AM/ethidium homodimer,
LIVE/DEAD assay. We verified that ZDON has no direct effect
on mitochondrial bioenergetics or antioxidant defences in
isolated mitochondria (Supporting Information Fig S7). These
studies are consistent with a model in which ZDON protects
mhtt expressing cells from a mitochondrial toxin via normal-
ization of mitochondrial gene expression.
To further establish the ability of ZDON to ameliorate
silencing of genes in a human context, we examined the effects
of ZDON in human myoblasts derived from patients diagnosed
with HD (Chaturvedi et al, 2009). As expected, an enhanced
expression of PGC-1a and cytochrome c in HD myoblasts was
detected by following treatment with ZDON (50mM for 2 h)
(Fig 4C). Normalization of gene expressionwas again associated
with resistance to 3-NP toxicity (Fig 4D). Altogether, these
studies establish the ability of ZDON to reverse the vulnerability
to mitochondrial toxins created by mhtt expression in rodent
and human cells.
Metabolic biomarkers after TG2 inhibition
To establish whether TG2 inhibition not only normalizes
metabolic gene expression, but also augments mitochondrial
function and mass, we measured several biomarkers of
mitochondrial metabolism in Q111 cells: citrate synthase (CS)
activity, ND6 protein levels and mitochondrial membrane
potential (Fig 5). We also performed bioenergetic studies in
isolated mitochondria (Supporting Information Fig S8). Citrate
synthesis is the first step of the TCA cycle and citrate is produced
from pyruvate to enter themitochondria in the form of acetyl Co-
A; accordingly CS has been used as an indirect measure of
mitochondrial number and mass. ZDON (50mM) treatment for
24 h increased CS specific activity approximately by 50% in both
the Q7 and the Q111 cells (Fig 5A). TheND6 subunit is necessary
for the proper formation and function of complex I, a component
of the respiratory chain (Chomyn, 2001). Although ND6 is a
protein encoded by the mitochondrial genome, the transcription
factors that regulate mtDNA expression are nuclear encoded
(Chomyn et al, 1985, 1986). Western blot analysis and
associated quantification revealed that ND6 levels were
significantly enhanced in Q111 cells after 24 h exposure to
ZDON (Fig 5B). Both these ZDON-induced changes (increased
CS specific activity and increased ND6 levels) reflect increases in
mitochondrial mass. To further evaluate the effect of ZDON on
mitochondrial mass, we utilized a Mitotracker1 dye that
passively diffuses across the plasma membrane and accumulates
in mitochondria in amounts proportional to the mitochondrial
membrane potential. The membrane potential represents an
electrochemical gradient, which upon dissipation via the F1–F0
ATPase can be converted to ATP. We measured Mitotracker1
staining 12 and 24h after treatment (50mM ZDON). ZDON
enhanced Mitotracker1 staining of Q7 and Q111 striatal cellswww.embomolmed.org EMBO Mol Med 2, 349–370(Fig 5C and D) providing additional support for a ZDON-mediated
increase in mitochondrial mass.
Studies of isolated mitochondria from Q7 and Q111 cells
supported the notion that CS and other TCA cycle enzymes
(SDH) are reduced by pathological polyQ expansions (not
shown). However, analysis of mitochondrial bioenergetics in
isolated mitochondria from Q7 with Q111 cells indicates several
unexpected observations. First, while it is clear that the total
number of mitochondria are reduced (likely related to clear
silencing of PGC1a and cytochrome c), the oxidative phosphor-
ylation and respiratory chain activity of each are not impaired in
Q111 cells, despite clear silencing of PGC-1a and cytochrome c
gene expression. Moreover, despite its ability to normalize PGC-
1a and cytochrome c mRNA levels and increase mitochondrial
mass, ZDON does not increase basal or maximal respiratory
capacity of Q111 cells. In fact, the respiratory data indicate that
mitochondria from Q111 cells are capable of higher spare
respiratory capacity and higher maximum respiratory rate than
their ‘WT’ counterparts in the absence of ZDON. Moreover,
ZDON does not increase total SDH activity, although, as
mentioned, it does increase CS activity (Fig 5A). The lower
activity of TCA cycle enzymes (CS and SDH per total protein)
and the higher-than-expected activity of mitochondrial electron
transport chain enzymes (respiratory control index, Vmax, etc.,
Supporting Information Fig S8) mean that Q111 mitochondria
are optimized for oxidations rather than biosynthesis. Accord-
ingly, Q111 cells are more vulnerable to TCA cycle toxins, such
as 3-NP (Fig 4B) which would further reduce the ability of Q111
mitochondria to provide electrons via NADH and FADH2 to the
mitochondrial electron transport chain for energy generation.
The increase in CS by ZDON raises the possibility that ZDON
acts to improve cellular energetic status by increasing the
number of mitochondria to create resistance to 3-NP. Para-
doxically, we do not see a similar increase in another TCA
cycle enzyme such as SDH (Fig 5A). Therefore, we cannot
exclude the possibility that TG2 inhibition induces resistance
to 3-NP by increasing the ability of extramitochondrial sites to
generate substrates that can be used in the mitochondria.
Examples of utilizable substrates from extramitochondrial
sites include pyruvate (generated from lactate via actions
of lactate dehydrogenase) or short chain fatty acids. Alterna-
tively, ZDON could interfere with death signalling cascades
downstream of ATP depletion. However, our isolated and
cellular mitochondrial studies in Q7 and Q111 cells point to a
more complicated model for ZDON-induced protection from
3-NP, which extends beyond PGC-1a cytochrome c and
mitochondrial-based metabolic compensation. The notion
that metabolic abnormalities derive from extramitochondrial
rather than mitochondrial sites is not new (Lee et al,
2007).
Transcriptome analysis following TG2 inhibition reveals
selective upregulation of several classes of genes
While TG2 inhibition leads to increased expression of genes that
drive mitochondrial mass, the unexpected lack of increased
respiratory function or capacity per mitochondria by ZDON
raises the possibility that other genes might be regulated by TG2 2010 EMBO Molecular Medicine 357
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Figure 5. TG2 inhibition by ZDON increases markers of mitochondrial mass (A), nuclear encoded mitochondrial protein expression (B) and increases
mitochondrial membrane potential (C, D) but does not improve mitochondrial bioenergetics in isolated mitochondria (Supporting Information Fig S8).
A. CS specific activity was increased after 24 h of ZDON treatment. CS is the enzyme that converts pyruvate to Acetyl-CoA is an accepted marker of mitochondrial
mass (Chavez et al, 2010).
B. ND6 was increased relative to b-actin in Q111 cells after 24 h treatment of ZDON. Nuclear encoded mitochondrial transcription factor A (Tfam) is a PGC-1a
regulated gene. Tfam, in turn, acts in the mitochondria to induce ND6 expression. The induction of ND6 by ZDON is consistent with ZDON-induced increases in
PGC-1a expression and activity.
C. Mitotracker1 staining was increased in both Q7 and Q111 cells after ZDON treatment. Mitochondrial mass is increased by ZDON in both Q7 and Q111 cells.
According to the bioenergetic studies the increase in membrane potential could reflect an increase in the biosynthetic capacity of respiratory chain substrates
by mitochondrial (TCA cycle) or extramitochondrial sites (pyruvate, fatty acids) by ZDON.
D. Quantification of Mitotracker1 staining with and without the addition of ZDON (50mM for 12 h).
p< 0.05 and p< 0.01.
358inhibition to account for the resistance to metabolic stressors
such as 3-NP. We also were interested in establishing the
specificity of gene changes induced by ZDON in Q7 versus Q111
cells. To begin to address these questions, we performed
microarray analysis on RNA purified from Q7 and Q111
immortalized striatal cells, before and after treatment with
ZDON. We also tested two additional, structurally diverse TG2
inhibitors, Boc-DON, already described in literature as a specific 2010 EMBO Molecular MedicineTG2 inhibitor (Parameswaran et al, 1990) and the broad TG2
inhibitor, cystamine (Bailey & Johnson, 2006), to exclude any
off target effects of ZDON. Expression of mhtt in Q111 cells
induced dysregulation of 461 probes (289 upregulated, 172
downregulated, p< 0.005) compared to Q7 (Q111 Not Treated
in Fig 6A). This profile of gene expression is similar to that found
by MacDonald and colleagues in their analysis of gene
expression in Q111 versus Q7 cells (microarray analysis, GEOEMBO Mol Med 2, 349–370 www.embomolmed.org
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Figure 6. ZDON normalizes the expression ofmany genes repressed in Q111 cells and it acts independently of HDACs to enhance cytochrome c and PGC-1a
expression levels.
A. Q111 cells have 461 dysregulated probes, relative to Q7 cells, and ZDON had a large effect (more than 40% of dysregulated genes) in normalizing this
dysfunction. Ontology gene sets affected by ZDON are broad and include p53-regulated genes, glutathione metabolism genes and chaperone genes.
B. Prototypical HDAC inhibitors NaBu or TSA increased the amount of PGC-1a mRNA in Q111 cells. These findings demonstrate that ZDON induces PCG-1a mRNA
expression as well as NaBu or TSA.
C. ZDON does not affect the acetylation state of H4 as measured by immunoblotting. As expected, the classes I and II HDAC inhibitor TSA increased H4 acetylation.
ZDON works independent of canonical changes in histone acetylation to modify transcription. These results are congruent with an HDAC independent role for
TG2 in epigenetic regulation.
p< 0.05 and p< 0.01.
D. WT TG2 interacts with Histone H3 in Q7 and Q111 cells supporting the evidence that TG2 modulates transcription. The ability of TG2 to interact with Histone
H3 is consistent with a role for TG2 in modulating facultative heterochromatin formation by affecting N-terminal post-transcriptional modifications of
histones, also known as the ‘histone code’.Dataset GSE21237; Lee et al, 2007). Of note, promoter analysis
of the 461-dysregulated probes revealed an over-representation
of Sp1 targets (p¼ 0.0047), congruent with previous reports
involving Sp1 in HD pathogenesis (Chen-Plotkin et al, 2006).
Ingenuity pathway analysis revealed dysregulation of networks
centred on Ppar-g and NF-kB (Supporting Information Fig S9).
Ppar-g was significantly upregulated in Q111 striatal cells,
whereas Pparc1 (PGC-1a gene) was slightly downregulated,
consistent with prior reports (Fig 1A). ‘transcription factor
activity’, ‘nucleosome’ and ‘programmed cell death’ were
among the most represented gene ontology (GO) categories
(Supporting Information Fig S10, microarray analysis- GEO
Dataset GSE21237).
We next assessed the extent to which ZDON treatment was
able to rescue the transcriptional dysregulation caused by Q111
expression. One hundred and ninety-six out of the 461 (42%)
Q111-related probes showed at least a 25% shift towards normal
levels (or levels in Q7 cells) after treatment with ZDON. Of these,
10 probes were completely restored to normal levels afterwww.embomolmed.org EMBO Mol Med 2, 349–370treatment. GO analysis showed that 40% of the genes in the
top categories tended toward normalization. The structurally
diverse TG2 inhibitors Boc-DON and cystamine (which both
protect against 3-NP toxicity, not shown) produced a similar
normalization in gene expression patterns in the mutant line
(37 and 38%, respectively), but ZDON was the most effective in
normalizing gene expression relative to Q7 untreated cells
(Q111 ZDON vs. Q111 No Treat, Fig 6A). ZDON treatment at
least partially reversed all the pathogenic changes observedwith
mhtt in histone genes, demonstrating that TG2 has a major
direct effect on chromatin remodelling and transcriptional
dysregulation in HD. ZDON treatment in normal Q7 striatal cells
had no effect on any of these genes demonstrating the selectivity
of TG2 inhibition for genes dysregulated bymhtt. Of note, ZDON
also restored expression levels for one HSP40 family member,
DNAJB10 (p< 0.05) in the microarray; increased DNAJB10
message by ZDON in Q111 cells was confirmed by quantitative
real time RT-PCR (Supporting Information Fig S11). Previous
studies showed that cysteamine, an FDA approved TG2 2010 EMBO Molecular Medicine 359
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360inhibitor, can also normalize DNAJB10 levels, and thus
increases brain-derived neurotrophic factor (BDNF) trafficking,
BDNF levels and neuroprotection in HD (Borrell-Pages et al,
2006). Altogether, our microarray analysis suggests that ZDON
normalizes expression of a large subset of genes, particularly
those dysregulated in HD. These findings are consistent with a
model in which increased TG2 acts in the nucleus at gene
promoters to dysregulate expression of metabolic, chromatin,
chaperone and cell death genes in HD. The normalization of
these genes by structurally diverse TG2 inhibitors in a cellular
model of HD provides indirect support for increased activity of
nuclear TG2 observed by numerous other groups in prior mouse
and human studies (Jeitner et al, 2008; Karpuj et al, 1999, 2002).
TG2 modulates transcription independently of HDACs
The ability of TG2 inhibition to normalize so many genes in HD
raised the possibility that ZDON might be acting directly or
indirectly to inhibit histone deacetylases (HDACs) in normal-
izing transcription in rodent and human cells. HDACs are
proteins that regulate transcription by acetylating N-terminal
tails of histone proteins and modulating facultative hetero-
chromatin (Sleiman et al, 2009); alternatively or in concert they
act by directly modifying the acetylation states of transcription
factors or coactivators to recruit the basal transcriptional
machinery (Ryu et al, 2003). To verify that ZDON is not acting
as an HDAC inhibitor, we compared its effects on histone
acetylation to canonical HDAC inhibitors.
HDAC inhibitors are known to reverse transcriptional
silencing in HD and to protect striatal neurons expressing
mutant htt from a host of stresses (Steffan et al, 2001). Sodium
butyrate (NaBu, a class I HDAC inhibitor) and Trichostatin A
(TSA, an inhibitor of class I and II HDACs) regulated the
cytochrome c promoter–reporter levels to an extent similar to
that exhibited by ZDON (data not shown), and these compounds
also increased the mRNA levels of PGC-1a (Fig 6B). Histone H4
acetylation, which is associated with a transcriptionally active
conformation of chromatin, was increased by HDAC inhibitors
and was unaffected by ZDON (Fig 6C). Moreover, ZDON and
HDAC inhibitors in combination did not alter global H4
acetylation levels as compared to HDAC inhibitors alone. These
findings suggest that TG2 inhibition acts independently of
HDAC inhibition to reverse transcriptional repression of PGC-1a
and cytochrome c in an HD model.
If TG2 inhibition acts independently of histone acetylation,
how is TG2 then binding to chromatin and modulating
transcription in the presence of mhtt? One obvious possibility
is that mhtt (with its abundant polyQ residues) is recruiting TG2
(an enzyme which crosslinks glutamines and lysines or
polyaminates glutamine residues) to relevant promoters to
silence (or augment) gene expression. However, co-immuno-
precipitation experiments using antibodies to full-length mhtt or
N-terminal fragment of mhtt failed to identify any TG2 bound to
either form of the protein (Zainelli et al, 2005), nor is ZDON
directly affecting mhtt levels to affect resistance to mhtt toxicity.
In contrast, parallel experiments using amonoclonal antibody to
Histone H3 identified a clear interaction between H3 and TG2 in
the nuclei of Q111 cells (Fig 6D). These findings, which are the 2010 EMBO Molecular Medicinefirst to document an interaction of TG2 with histone proteins in
an intact cell, are consistent with prior test tube experiments that
have shown that TG2 can post translationally modify histone
proteins (Ballestar et al, 1996, 2001; Ballestar & Franco, 1997).
In addition, they are consistent with a model where TG2
interacts with Histone H3 to polyaminate its N-terminal tail
leading to increased electrostatic interaction between positively
charged histone proteins and negatively charged DNA. Inhibi-
tion of TG2 would reduce polyamination of the N-terminal of
histones including Histone H3, decrease positive charge on
histone proteins, reduce interaction with DNA and promote an
open, transcriptionally active conformation leading to reversal
of transcriptional silencing in HD.
ZDON is protective in an HD fly model
The ability of ZDON to normalize genes belonging to many GO
groups predicts that ZDON should not only protect against 3-NP
vulnerability but also reduce mhtt-induced neurodegeneration.
ZDON is a peptide-based inhibitor, which presents obvious
challenges in penetrating the blood brain barrier. To establish
whether ZDON can protect against neurodegeneration induced
by mhtt in vivo, and to avoid some of the problems associated
with delivering peptides into the CNS in rodents, we examined
the effect of ZDON in an established Drosophila model of HD
(Agrawal et al, 2005; Marsh & Thompson, 2006; Steffan et al,
2001). This model has been extensively studied and expresses
an exon 1 fragment of mhtt that contains a 93 glutamine repeat
under control of a pan neuronal driver (elav, using the UAS Gal4
system) (Agrawal et al, 2005). Neuronal degeneration can be
measured in this model by counting the number of surviving
photoreceptor neurons as reflected by the number of rhabdo-
meres in each ommatidium in the eye. WT flies have seven
visible rhabdomeres per ommatidium, but as HD flies age there
is a loss of rhabdomere number, thus providing a readily
measurable biomarker of mhtt-induced degeneration. ZDON is
soluble in dimethyl sulphoxide (DMSO), which is highly toxic to
the Q93 flies; therefore we conducted toxicity studies to
determine the amount of DMSO-dissolved ZDON that could
be tolerated by the Drosophila without causing overt toxicity
(Fig 7B). The highest non-toxic, final concentration of ZDON in
the food was found to be 125mM, and this concentration was
then tested for its ability to inhibit TG2 activity in fly head
homogenates using an in vitro TG activity assay. Drosophila
have only one form of TG, which contains the same catalytic
triad and Ca2þ-binding site as TG2 but lacks the GTP-binding
activity (Ikle et al, 2008). Flies fed food containing 125mM
ZDON showed an 80–90% decrease in TG activity without
apparent toxicity (data not shown) and an increase in the
number of rhabdomeres at 10 days of age as compared to those
fed vehicle (Fig 7A). One group of control flies was given no
DMSO, and another control group was given DMSO alone
(approx. 0.2%) with no ZDON. There was no significant
difference between the two control groups.When percent rescue
was calculated with the equation: 100 (RtRc)/(7Rc), Rt is
the number of rhabdomeres/ommatidium in the ZDON group
and Rc is the control group, ZDON showed a significant rescue
relative to DMSO only fed flies (21%). In addition to the increaseEMBO Mol Med 2, 349–370 www.embomolmed.org
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Figure 7. TG2 inhibition by ZDON is protective in a fly model of HD.The ability of ZDON to affect a broad swath of genes dysregulated bymhtt led us to test
the ability of ZDON to prevent mhtt induced degeneration in photoreceptors.
A. A Drosophila HD model expressing exon 1 of htt with 93 CAG repeats (Q93) fed ZDON (125mM final concentration in food) displayed a greater number of
rhabdomeres per ommatidium than HD Q93 flies receiving no treatment (control) or DMSO alone (Vehicle).
B. This was calculated as a 21% rescue from DMSO and a 17% rescue from the control group by the formula: 100 (Rt Rc)/(7Rc), Rt is the number of
rhabdomeres/ommatidium in the ZDON group and Rc is the control group.
C. A Drosophila model of HD fed ZDON (125mM final concentration in food) showed increased cytochrome c mRNA when compared to those that were not fed
ZDON (control) or those fed only DMSO.
p< 0.05 and p<0.01.of rhabdomere number, ZDON fed Drosophila also displayed
augmented cytochrome c mRNA levels (Fig 7C). These studies
suggest that ZDON-induced neuroprotection is associated with
reversal of transcriptional dysregulation in a fly model of HD.
TG2 inhibition protects from NMDA toxicity in YAC128
primary neurons
To establish whether neuroprotection from mhtt-induced
neurodegeneration by ZDON can be observed in the cell type
most vulnerable to degeneration in HD, we studied excitotoxic
death in striatal neurons cultured from YAC128 mice. Several
studies support the hypothesis that mhtt contributes to
increased neuronal susceptibility to excitotoxicity, a state in
which aberrant stimulation of neurons leads to their death
(Heng et al, 2009; Okamoto et al, 2009; Zeron et al, 2002).
N-methyl-D-aspartate acid (NMDAs) toxic effect in HDmice and
cellular models has been attributed to cytosolic calcium
overload or to increased mitochondrial depolarization (Browne,
2008; Fernandes et al, 2007). Furthermore, NMDA activation
has been recently reported to induce repressive transcription via
extrasynaptic NMDA receptors in YAC128 mice, a knock in
mouse model for HD (Okamoto et al, 2009). To explore the
possible involvement of TG2 in extrasynaptic glutamate
mediated transcriptional repression, we pre-treated medium-
sized spiny neurons (MSNs) with ZDON and its negative controlwww.embomolmed.org EMBO Mol Med 2, 349–370Zc for 12 h, then incubated the cultures in a balanced salt
solution in the presence of NMDA (500mM). As previously
reported (Graham et al, 2006), cultured YAC128 MSNs
displayed increased apoptosis 24 h after NMDA exposure
compared with WT MSNs (YAC128¼ 31.9 1.03% vs.
WT¼ 21.3 1%; Fig 8A and B). Interestingly, TG2 inhibition
protected both WT and mutant MSNs from NMDA toxicity
(YAC128¼ 13.1 3.4% vs. WT¼ 9.8 1.4%) and its effect was
more dramatic in the presence of mhtt (7% increase in
protection). The use of Zc did not have any effect on NMDA
toxicity (YAC128¼ 27 2% vs. WT¼ 21 1.3%; Fig 8B).
These experiments show that TG2 inhibition protects
vulnerable striatal neurons from NMDA toxicity in the presence
or absence of mhtt. Given that recent studies have shown that
PGC-1a is sufficient to prevent NMDA toxicity in YAC128 striatal
neurons (Okamoto et al, 2009), the finding herein that TG2
inhibition is sufficient to reduce mhtt-induced repression of
PGC-1a offers a logical mechanism by which ZDON is protective
in this model.DISCUSSION
Despite extensive genetic and pharmacological studies (Bailey &
Johnson, 2006; Dedeoglu et al, 2002; Mastroberardino et al, 2010 EMBO Molecular Medicine 361
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Figure 8. Effect of ZDON and control peptides on NMDA-induced toxicity in MSN cultures from WT and Y128 mice.
A. TUNEL assay (a biomarker of apoptotic death) of medium-sized spiny neurons following 24 h of NMDA exposure. The MSNs pre-incubated with ZDON (50mM)
for 12 h showed less apoptotic nuclei that the ones untreated or pre-treated with Zc (50mM), demonstrating the protective effects of TG2 inhibition against
NMDA-mediated toxicity. Extrasynaptic NMDA induces changes in cytosolic calcium sufficient to further activate TG2 and repress adaptive transcription. We
propose a model whereby TG2 inhibition prevents extrasynaptic glutamate from inducing transcriptional dysregulation and leads to neuroprotection.
B. Quantification of Fig 8A.
p<0.01, comparing WT to Y128; ###p<0.001, comparing to NMDA treatment group of its genotype.
3622002; Van Raamsdonk et al, 2005), the precise mechanism(s) by
which TG2 mediates deleterious effects in HD remain(s)
obscure. Here, we provide evidence that TG2 participates with
mhtt to induce broad dysregulation of gene expression in a well- 2010 EMBO Molecular Medicinestudied and validated mouse model of HD (Q111). As expected,
inhibition of TG2 by structurally diverse, low molecular weight
inhibitors relieves a significant level (40%, Fig 6A) of
transcriptional dysregulation and is associated with resistanceEMBO Mol Med 2, 349–370 www.embomolmed.org
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show that nuclear TG2 requires its transamidating activity to
influence cytochrome c and PGC-1a transcription by binding
chromatin and we also demonstrate an interaction between TG2
and Histone H3 in Q7 and Q111 cells. These findings are
consistent with a model whereby TG2 polyaminates N-terminal
tails of histones to modulate facultative heterochromatin
formation and thus affects a large number of genes associated
not only with nucleosomes and chromatin remodelling, but also
genes related to chaperone, programmed cell death and
metabolic function. Our data provide unexpected pathophysio-
logical convergence between two previously disconnected
aspects of HD pathogenesis: nuclear TG hyperactivity and
transcriptional dysregulation.
Within the eukaryotic nucleus, DNA is organized by its
incorporation into chromatin. The basic subunit of chromatin is
the nucleosome, which is composed of DNA coiled around an
octamer of histone proteins, twomolecules each of histone H2A,
H2B, H3 and H4. Histone H1 associates with chromatin outside
the nucleosome (Sleiman et al, 2009). The amino-terminal ‘tail’
of each histone is evolutionarily conserved and it is target of
numerous post-transcriptional modifications. Post-translational
modifications of histones are major players in epigenetic
control. These modifications include the acetylation, methyla-
tion, phosphorylation, ADP-ribosylation and monoubiquitina-
tion. The specific pattern of histone modification, or ‘histone
code’, is used by proteins involved in chromatin organization to
establish a transcriptionally silent or active state (Ratan, 2009).
Here, we provide data supporting the idea that TG2may catalyse
polyamine addition to histones that might add additional
complexity to the ‘histone code’. Polyamines are organic
compounds that have two or more amino groups. Alone or
when covalently attached to a protein, they bind DNA readily,
but unlike Ca2þ, their positive charge is spread evenly
throughout the molecule. Their avidity for DNA on a charge
basis makes them ideally suited to regulate the conformation
of DNA. Attaching them to proteins (via TG2) provides an
elegant way to manipulate polyamine concentrations (organic
cations) locally to be able to alter propensity for DNA (highly
negatively charged due to phosphate backbone) to assume a
compact (silenced) conformation. By contrast, suppression of
TG2 should inhibit polyamination of histone protein, thereby
decreasing histone–DNA interactions and increasing gene
expression. In a number of test tube studies, polyamination of
glutamines in histone tails by TG has been shown to occur.
Indeed, Ballestar (Ballestar & Franco, 1997) showed that TG2
polyaminates glutamine 5 and 19 of HistoneH3 and glutamine 22
of histone 2B. Our study is the first to demonstrate an interaction
between TG2 and any histone protein in an intact cell, and the
first to conclusively demonstrate a role for nuclear TG2 in gene
regulation. While we clearly show that TG2 inhibition works
independently of HDAC inhibition to augment transcription
(Fig 6D), future studies will define whether hyperpolyamination
of histone tails is the mechanism by which TG2 hyperactivation
in HD contributes to gene silencing in this disease.
Identification of a cassette of genes modulated by TG2
inhibition can be utilized as an in situ biomarker for therapeuticwww.embomolmed.org EMBO Mol Med 2, 349–370strategies in HD centred on the inhibition of this intriguing
enzyme. Current activity measurements for TG2 only allow
measurement of maximal activity (Vmax) in a population of cells,
as they involve exogenous addition of a calcium ionophore to
cells in monolayer, which fully activates the enzyme (Support-
ing Information Fig S6B). Our gene array studies define a group
of genes (e.g. b-actin, p21waf1/cip1 and tp53inp1, mdm2) that are
highly upregulated (7- to 30-fold) by TG2 inhibition. Consistent
with prior observations of mhtt interacting with p53 (Steffan
et al, 2000), three of these genes are associated with p53
upregulation (p21waf1/cip1, tp53inp1, mdm2), particularly in p53
responses to oxidative stress. This gene cassette could reflect an
augmentation of the DNA damage response by ZDON, but also
could be used (via in situ hybridization) as a sensitive way to
monitor TG2 activity in vulnerable striatal neurons in animal
models of HD or in human autopsy tissue. By extension,
appropriate pharmacokinetics of inhibitors of the enzyme could
then be determined by assaying the point above which, the
levels of this cassette of genes in the striatum of rodents
expressing mhtt increase.
Our studies of TG2 involved in transcriptional silencing in
HD were stimulated by observations that this enzyme regulates
nodal genes in metabolic adaptation: cytochrome c and PGC-1a
(Fig 1). The reversal of mhtt-induced silencing of both of these
genes and a host of markers of mitochondrial mass and
function (CS, ND6 and mitochondrial membrane potential,
Fig 5) by ZDON seemed congruent with a straightforward
model: TG inhibition normalizes mitochondrial biosynthetic
and oxidation capacity to overcome metabolic defects in an HD
striatal lines. However, detailed mitochondrial bioenergetic
analyses suggest that this simple model is incorrect in Q111
cells. Indeed, mitochondrial oxidation capacity (electron
transport chain activities and oxygen utilization, Vmax) is
actually increased in Q111 as compared to Q7 cells. In fact, it
appears that in Q111 cells, the ability of the mitochondria to
synthesize substrate for oxidation (via the activity of TCA cycle
enzymes) is diminished (Supporting Information Fig S8). These
data are completely congruent with the increased vulnerability
of Q111 and human HDmyoblasts to 3-NP, a toxin that inhibits
TCA cycle enzymes (e.g. SDH and fumarase). However, the
absence of an increase in SDH message or activity by ZDON
refutes the simple notion that PGC-1a, a known coactivator of
mitochondrial biogenesis, is globally increasing all TCA and
respiratory chain components in response to TG2 inhibition
and thus creating resistance to 3-NP. Future studies will
determine the exact contribution of PGC-1a to protection by
ZDON in loss of function studies. Whatever the results, these
findings are consistent with prior observations from other
groups that mitochondrial oxidative phosphorylation is not
decreased in HD cells (Browne, 2008) and that in contrast, it is
increased. The diminished mitochondrial biosynthetic capacity
in Q111 cells (if extendable to rodent models and human
autopsy studies) has clear therapeutic implications. Strategies
to enhance substrate delivery to the mitochondrial respiratory
chain (e.g. via feeding pyruvate, malate, NADH, FADH2 or
short chain fatty acids) in HD patients may feed the ‘augmented
mitochondrial engine’ that Q111 cells possess and thus 2010 EMBO Molecular Medicine 363
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Methods to generate ATP from extramitochondrial sites in
striatal neurons are a reasonable alternatives (Lee et al, 2007).
Indeed, activators of glycolytic gene expression protect Q111
cells from 3-NP toxicity (Niatsetskaya et al, 2010) and small
molecules that reprogram metabolism are protective in more
complex HD models (Parker et al, 2005).
The inability of ZDON to improve mitochondrial bioenergetic
parameters raised questions regarding the mechanism by which
TG2 inhibition protects against mhtt-induced cell dysfunction
and death (Battaglia et al, 2007). We excluded the possibility
that ZDON (like cystamine or cysteamine) could directly inhibit
caspases or increase glutathione levels to mediate protection
(Supporting Information Figs S3 and S4). An unbiased analysis
of gene changes in Q111 cells subjected to structurally diverse
TG2 inhibitors resulted in broad normalization of not only
cytochrome c and PGC-1a, but also several hundred other genes
dysregulated by mhtt in Q111 cells (Fig 6A, microarray analysis
– GEO Dataset GSE21237). The findings support conclusions by
others that HD reflects gene dysregulation of many functions
(not only the mitochondria) (Benn et al, 2008). Indeed, the
classes of compounds most effective to date in pre-clinical
models are those that directly reduce mhtt levels (Krainc, 2010)
or modulate mhtt transcriptional dysregulation. Even the FDA
approved, use dependent, NMDA antagonist, memantine
appears to prevent transcriptional dysregulation of PGC-1a
(and likely other CREB dependent genes) induced by extra-
synaptic glutamate and excacerbated bymhtt (Milnerwood et al,
2010; Okamoto et al, 2009).
Non-selective class I or II HDAC inhibitors (phenylbutyrate,
valproic acid and HDAC inhibitor 4b) are being tested in humans
for HD and other neurological conditions (Kazantsev &
Thompson, 2008). Is TG2 inhibition in any way superior to
HDAC inhibition, if both act on histones to promote transcrip-
tion? Recent studies have highlighted some shortcomings of
non-selective HDAC inhibition: HDAC1 inhibition leads to DNA
damage in the CNS (Kim et al, 2008); the ability of HSP40
chaperones to reduce toxicity of polyQ proteins in cultured cells
is reduced byHDAC4 inhibition (Hageman et al, 2010). Together
these studies suggest that non-selective HDAC inhibition has
biological actions that potentially create toxicity and limit
efficacy of this approach. A number of groups are actively
developing isoform-selective HDAC inhibitors (that would
avoid inhibiting HDAC1 or HDAC4) for treatment of HD
(Rivieccio et al, 2009). Fortuitously, TG2 inhibition represents
an HDAC-independent, epigenetic strategy that normalizes
gene expression and like isoforms-selective HDAC inhibitors,
would similarly avoid the deleterious consequences of
HDAC1 or HDAC4 inhibition. Additionally, the magnitude of
transcriptional normalization by TG2 inhibition (nearly 40%)
appears to be equivalent to that of HDAC inhibition (Thomas et
al, 2008). Given the existence of established inhibitors for
HDACs and the elucidation of a selective TG2 inhibitor herein
(ZDON), a head-to-head comparison of TSA or butyrate to
ZDON, or a combination of two of these is in order. Indeed, a
prior study showed a 40% increase in survival in R6/2 mice
treated with a combination of a DNA binding drug, mithra- 2010 EMBO Molecular Medicinemycin and the non-selective TG2 inhibitor, cystamine (Ryu
et al, 2006).
Another exciting aspect of the current study is their ability to
clarify and extend prior observations from several groups
working on TG2 and HD. Karpuj and Steinman first showed that
the non-selective TG2 inhibitor, cystamine reverses transcrip-
tional dysregulation in an HD model. Specifically, they showed
that one of the HSP40 chaperones, DNAJB10 (which by itself can
reduce poly Q toxicity) was increased in cystamine treated mice
(Karpuj et al, 2002); however they did not provide a model for
how TG2 inhibition could increase DNAJB10 transcription.
DNAJ message and protein levels were subsequently confirmed
to be reduced in brains from HD patients. The FDA approved,
TG2 inhibitor cysteamine also increased DNAJ (HSJ1b)
transcription and protein levels in striatal neurons in vitro
and protected worms (Caenorhabditis elegans) from the toxic
effects of mhtt (Borrell-Pages et al, 2006). Cysteamine enhanced
trafficking of BDNF by inhibiting TG2 function at the Golgi
apparatus, but the role of TG2 in DNAJ transcription was, again
not examined. Microarray studies herein showed that ZDON can
significantly increase DNAJB10 expression, a finding that was
validated by quantitative real time RT-PCR (Supporting
Information Fig S11). These studies as well as our results
showing that TG2 binds to chromatin to repress transcription
support a role for this enzyme in silencing the expression of an
important chaperone (HSJ1b) that increases mhtt proteotoxi-
city. While the relationship between ZDON-induced increased
PGC-1a expression and ZDON-induced protection remains
unclear, the mechanism by which ZDON-induced changes in
DNAJ (HSJ1b) expression would lead to neuroprotection are
well established by these prior studies (Borrell-Pages et al, 2006;
Hageman et al; Karpuj et al, 2002). Moreover, prior studies
showed that increases in cytosolic calcium consequent to
glutamate receptor hyperactivation lead to activation of TG2 and
cell death (Milnerwood et al, 2010; Okamoto et al, 2009).
Consistent with these observations, TG2 inhibition protected
striatal neurons fromWT and YAC128mice fromNMDA toxicity
by TG2 inhibition (Fig 8). From these data, a model can be
generated whereby TG2 participates with mhtt to silence the
expression of many genes in neurons (and presumably
astrocytes) including those involved in the generation of ATP
and those involved in glial glutamate transport. Reductions in
ATP contribute to excessive NMDA receptor activation
(particularly extrasynaptically) by energy-dependent loss of
theMgþþ block (Beal et al, 1993) or by diminished scavenging of
glutamate by astrocytes (Bradford et al, 2009, 2010; Fig 8).
Excessive activation of extrasynaptic NMDA receptors, leads to
receptor mediated increases in cytosolic calcium and activation
of TG2 (a calcium-regulated enzyme), further enhancing
transcriptional repression of many genes, including PGC-1a,
BDNF and DNAJ chaperones (Milnerwood et al, 2010; Okamoto
et al, 2009; Figs 1A and 4A, Supporting Information Fig S11).
Repression of these and other genes contributes to dysfunction
and ultimately death of neurons. Inhibition of TG2 positively
influences function and survival, not only by normalizing gene
expression in neurons and possibly astrocytes (nuclear function
of TG2), but also by enhancing trafficking of BDNF (via cytosolicEMBO Mol Med 2, 349–370 www.embomolmed.org
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et al, 2008). Altogether these studies suggest that both nuclear
and cytosolic TG2 contribute importantly to HD pathogenesis
and should heighten interest in the development of novel small
molecule inhibitors of TG2 to consolidate the advances
subsequent to our identification and characterization of the
selective TG2 inhibitor, ZDON.MATERIALS AND METHODS
TG inhibitors
ZDON and Boc-DON were obtained from Zedira (Darmstadt, Germany).
Cystamine was obtained by Sigma–Aldrich. The Boc-DON peptide was
known from the literature (Parameswaran et al, 1990). IC50 studies
involving recombinant TG2 were performed, as described in Support-
ing Information. Of note, our initial studies with ZDON defined
incubation times appropriate to inhibit TG2 in a test tube assay
(McConoughey et al, 2009). Our empirical experience has been that
different cell types respond to ZDON differently likely because they
express different levels of TG2 and have different capacity to transport
and metabolize the peptide ZDON. For that reason we monitored
incubations to find the shortest period of time before we observed an
increase in cytochrome c and PGC-1a transcription by RT-PCR; this
correlated well with global changes in TG2 activity (not shown). As
expected, for the reasons outlined above these incubation times were
different for different cell types.
Cell culture conditions
STHdhQ7 and STHdhQ111 cells were maintained in Dulbecco’s modified
Eagle medium (Invitrogen, Carlsbad, CA) containing 25mM D-glucose,
1mM L-glutamine and supplemented with 10% fetal bovine serum
(FBS), 1mM sodium pyruvate and 400mg/ml geneticin (Invitrogen). All
cells were incubated at 338C with 5% CO2. Cells were not used after
they reached 15 passages. WT and TG2/ MEFs were kept at 378C with
5% CO2 in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% FBS.
Plasmids
Full-length cytochrome c promoter reporter plasmid (pGL3RC4/-326)
was used as previously described (Herzig et al, 2000).
Doxycyline-Inducible Q103 (mutant Htt)-EGFP neuronal
cell lines
The T-RExTM System (Invitrogen, Carlsbad, CA) was used to generate
Q103-enhanced GFP (EGFP) cell lines. This system utilizes two vectors,
the pcDNA6/TR vector, a regulatory plasmid that expresses the
tetracycline repressor (TetR), and pcDNA4/TO, which contains a
cytomegalovirus (CMV) promoter driving the expression of the gene
of interest under the control of Tet-operator sequences. Q103-EGFP
was subcloned into the pcDNA4/TO vector from pcDNA-Q25- and
Q103-EGFP construct, in which exon 1 of mhtt is cloned to an EGFP
fusion vector (Clontech, Mountain View, CA). pcDNA4/TO-Q103-EGFP
was linearized and transfected into SH-SY5Y cell clone over expressing
pcDNA6/TR. The Q103-EGFP cell clones were selected by zeocin. For
the induction of Q25- and Q103-EGFP, 3–10mM of doxycyline was
treated into culture medium.www.embomolmed.org EMBO Mol Med 2, 349–370Transglutaminase 2 constructs
WT TG2 and the transamidating-defective isoform (C277V TG2) have
been previously described (Antonyak et al, 2002); NES TG2 was
obtained by introducing the NES of HIV Rev (LPPLERLTL) (Fischer et al,
1995) to the N terminal of Myc-TG2. The NN TG2 has the NES
sequence at the N-terminal of Myc-TG2 and a mutation at the NLS
sequence in position 597–602 (PKQKRK! PKQAAK). The mutations
were generated using a site-directed mutagenesis method (Quick-
change Constructs mutation kit, Stratagene). Constructs were
confirmed by DNA sequencing.
Total lysate
For total TG2 expression, cells were harvested in cold phosphate
buffered saline (PBS), centrifuged at 3000 g at 48C and resuspended
in lysis buffer (50mM Tris–HCl pH 7.4, 1% Triton X-100, 100mM NaCl
and protease inhibitor cocktail).
Immunofluorescence
Q7 cells expressing the Myc-pCDNA3 vector, Myc-TG2 WT, Myc-TG2
NES or Myc-TG2 NN were fixed using 4% paraformaldehyde,
permeabilized with 0.1% Triton X-100, and then incubated with a
c-Myc antibody (Covance, USA). The c-Myc antibody was detected
using an Alexa green 488-conjugated secondary antibody, and DAPI
was used to stain the nuclei.
Immunoprecipitation
Myc-TG2 was immunoprecipitated from a total cell lysate (600mg)
using the IP/CoIP Myc kit, according to the manufacturer’s instructions
(Pierce).
Western blotting
Lysates from cells were centrifuged at 10,000 g for 10min at 48C,
and the protein concentration was measured using the Bradford Assay
(Bio-Rad). Thirty micrograms of proteins was loaded into each well,
run on NuPAGE1 Bis-Tris Gels (4–12%), and transferred to a
nitrocellulose filter for blotting. The primary antibodies used were
anti-ND6 (Santa Cruz Biotechnology) at a 1:500 dilution in blocking
buffer and anti-b-actin (Sigma) at 1:5000. All secondary antibodies
were dye-labelled (LI-COR Biosciences, USA).
Histone precipitation
Harvested cells were resuspended in hypotonic lysis buffer. The lysate
was centrifuged at 15,000 g for 10min at 48C, and then
resuspended in 200ml of 0.4N H2SO4 and rotated overnight at 48C.
The homogenate was then centrifuged at 21,000 g for 10min at
48C, and the resulting supernatant was transferred to a fresh tube. The
histones were precipitated, incubated on ice for 30min, and then
centrifuged at 13,000 rpm for 10min at 48C and the resulting pellet
contained the histones. The histones were dissolved in Western blot
loading buffer, and the acetylated histones were revealed with anti-
acetyl H4 at 1:500 (Millipore) and total H4 were detected with anti-
H4 at a 1:1000 dilution (Millipore).
Microarray analysis
Total RNA was extracted from Q111 and Q7 striatal cell lines, after
12 h treatment with ZDON (50mM), Boc-DON (50mM), cystamine
(250mM) or control treatment. Three replicates were run per sample 2010 EMBO Molecular Medicine 365
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366category, for a total of 24 arrays. RNA quantity was assessed with
Nanodrop (Nanodrop Technologies) and quality with the Agilent
Bioanalyzer (Agilent Technologies). Total RNA (200ng) was amplified,
biotinylated and hybridized on Illumina Mouse Mouseref-8 Expression
Beadchips v1.1, querying the expression of 22,000 Refseq tran-
scripts, as per manufacturer’s protocol. Slides were scanned using
Illumina BeadStation and signal extracted using Illumina BeadStudio
software (Illumina, San Diego, CA). Raw data were analysed using
Bioconductor packages (www.bioconductor.org). Quality assessment
was performed looking at the interarray Pearson correlation and
clustering based on top variant genes was used to assess overall data
coherence. One sample (Q7 cells treated with Boc-DON) failed the QC
test and was excluded from further analysis. Contrast analysis of
differential expression was performed using the LIMMA package
(Smyth et al, 2005). After linear model fitting, a Bayesian estimate of
differential expression was calculated. Data analysis was aimed at (1)
identifying transcriptional changes in the Q111 compared to Q7
striatal cell line, and (2) the effect of drug treatment on gene
expression abnormalities. The threshold for statistical significance was
set at p<0.005. The raw gene-expression data are available at
www.ncbi.nlm.nih.gov/geo (GEO Dataset, GSE21237). GO and Pathway
analysis were carried out using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) and Ingenuity Pathway
Analysis (www.ingenuity.com). For Promoter analysis methods see
Supporting Information Section.
Citrate synthase specific activity assay
Q7 and Q111 cells were harvested, and 50mg of lysate was
added to each well of a 96-well plate containing: 120ml of 100mM
Tris Buffer (Sigma), 20ml of 2mM acetyl CoA (Sigma), and and 20ml of
2.5 mM 5,50-dithio-bis-(2-nitrobenzoic acid) (DTNB) (Sigma).
Background readings were done at 378C for 5min at 412 nm,
after which 20ml of 2mM oxaloacetate (Sigma) was added to each
well. OD was measured at 412nm for 30min. The rate of CS specific
activity of ZDON treated cells was quantified relative to non-treated
cells.
Mitotracker staining1
Q7 and Q111 were treated with ZDON 50mM for 12 h, washed with
pre-warmed Hank’s balanced salt solution (HBSS) and incubated with
MitoFluor Red 594 probe (Invitrogen) at a final concentration of
100nM for 30min. The dye was removed from the supernatant and
the cells were analysed with the axiover 200 epi-fluorescence
microscope (Zeiss).
Chromatin immunoprecipitation assay
A ChIP assay kit was used as directed by the manufacturer (Millipore).
Briefly, cells were cross-linked with formaldehyde (1% for 10min at
378C). Cells were sonicated and immunoprecipitated with primary
antibodies (15mg) against TG2 (NeoMarkers) and anti-rabbit IgG
(Santa Cruz or Millipore). The crosslinking was reversed, and the DNA
was isolated either through phenol/chloroform extraction or on DNA
columns (Millipore). Using an Applied Biosystems 7500 Fast Real Time
PCR System, PCR reactions were conducted either using Taqman
labelled primers targeted to the cytochrome c promoter (forward,
GTTACCTGAGCCGAGCCACAC; reverse, TGACGTAACCGCACCTCATTGG)
or using SYBR GREEN Master Mix and primers amplifying the 2010 EMBO Molecular MedicinePGC-1a gene (forward, TTGCTAGCGGTCCTCACAGA; reverse,
GGCTCTTCTGCCTCCTGA).
Luciferase assay
Q7 and Q111 cells were transfected with the cytochrome c promoter–
reporter and a pTK-Renilla control (Promega). Luciferase activity was
measured by a dual luciferase assay (Promega) and normalized to
Renilla activity using a bioluminator (Molecular Devices) according to
the manufacturers’ instructions.
Drosophila
Fly stocks were kept at 188C and moved to 258C for breeding and
experimentation. After the Q93 flies (w; P{UAS-Httex1p Q93}4F1)
were crossed with the elav (w; P{wþmW.hs¼GawB}elavC155), the
resulting offspring were moved to vials containing food supplemented
with DMSO, 125mM ZDON or water. At 10 days of age the flies were
decapitated and the heads were mounted on a microscopic slide with
nail polish. The rhabdomeres were analysed under oil emersion at 63X
to visualize individual rhabdomeres. The scoring (counting the
rhabdomeres for each ommatidium) was done blinded and the correct
labels were given only after all of the data were acquired. There were
15–20 flies used for each condition with 800–1000 ommatidia
counted for each group of flies (Control, DMSO and ZDON). RNA was
isolated from the heads of Drosophila through Trizol lysis and phenol–
chloroform extraction.
Transient transfection
Q7 and Q111 cells were plated in 96-well plates. Cells were
transfected using Lipofectamine 2000 (Invitrogen) as directed by the
manufacturer.
Cell viability
Q7, Q111 or primary neurons were plated in a 96-well Blackwell plate
and treated with 50mM ZDON. After 12 h, the medium was replaced
with low glucose media containing 10mM 3-NP. After 48 h, live cells
were visualized with LIVE/DEAD assay (Invitrogen). The wells were then
photographed using a flash cytometer and live cells were counted
with Trophos software (France).
Quantitative real time PCR
Either the Taqman RNA-to-Ct, one-step kit (Applied Biosystems) was
used according to the manufacturer’s instructions or reverse
transcription using Superscript 3 (Invitrogen) was conducted on
2mg of total RNA extracted from Q7 and Q111 cells. The cDNA was
then run with the Taqman1 Gene Expression Master Mix and
Taqman1 Gene Expression Assays for cytochrome c, PGC-1a, HSJ1b,
18S, on an Applied Biosystems 7500 Fast Real Time PCR System. The
resulting data were analysed using the delta delta CT method, and all
measurements were normalized to 18S mRNA.
RNAi
Three sequences of Stealth RNAi (Invitrogen; RNAi1: GGAGGGAGAC-
CUGAGUACCAAGUAU; RNAi2: CCUGCCUGAUGCUCUUGGAUAUGAA;
RNAi3: CCUGCCUGAUGCUCUUGGAUAUGAA) targeted against TG2
were transfected into Q111 cells using Lipofectamine 2000 (Invitro-
gen). Cells were grown in culture 24–48h after transfection, and RNA
was isolated to measure levels of cytochrome c, PGC-1a, TG2 or 18S by
qRT-PCR.EMBO Mol Med 2, 349–370 www.embomolmed.org
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Myoblasts derived from muscle biopsies were obtained from control
subjects and HD patients (Ciammola et al, 2006). The myoblasts were
cultured as previously described (Blau & Webster, 1981). Briefly,
myoblasts were grown in HAMs F10 medium (GIBCO, Invitrogen)
supplemented with 15% FBS (Invitrogen, San Diego, CA), 0.5mg/ml
bovine serum albumin, 4 ng/ml insulin, 10 ng/ml epidermal growth
factor, 0.39mg/ml dexamethasone, 0.1mg/ml streptomycin and
100U/ml penicillin.
NMDA induced cytotoxicity
Cultured MSNs (DIV 7 or 8) were pre-treated with 25mM, 50mM
ZDON or 50mM control Zc peptides for 12 h, then incubated in warm
balanced salt solution (BSS, pH 7.4) with or without 500mM NMDA
for 10min. MSNs were washed twice with warm plating medium (PM)
and then incubated in conditioned PM for 24 h.
TUNEL assay and assessment of apoptosis
Fixed MSNs were numbered according to different conditions and
coded before staining to ensure that the operator was blinded during
the subsequent processing and analysis of immunofluorescence. MSNs
were further permeabilized with 0.25% Triton X-100 in PBS with 0.5%
sodium citrate on ice for 2min. MSNs were then washed once with
PBS and incubated in PBS with 16mg/ml RNAse at RT for 30min.
MSNs were washed with PBS and incubated in TUNEL (Roche) reagent
(at a ratio of label/enzyme¼9:1) per well in the dark for 1 h, followed
by one wash with PBS and staining with 10mM Hoechst 33342.
MSNs were then washed with PBS and mounted on slides with
Fluoromount-G. The second day after staining, the percentage of
apoptotic cell death was assessed by counting the numbers of TUNEL
positive cells in the green fluorescent channel which also showed
condensed and blebbed nuclear morphology in the blue fluorescent
channel, then dividing by the total number of Hoechst positive cell
nuclei in the blue fluorescent channel and multiplying by 100. A total
of 1000 neurons were counted per condition. In each experiment,
apoptosis 24 h following 10-min treatment with BSS alone, without
NMDA, was assessed and the percentage was subtracted as a baseline
from the total cell death induced by NMDA in each experiment to
calculate the specific NMDAR-mediated apoptosis.
Statistics
All data were expressed as mean SEM and were plotted using
GraphPad Prism software. Analysis of variance was used to compare
means with one or two-way analysis of variance (ANOVA) and Tukey’s
or Bonferroni’s post hoc tests were applied accordingly when
significance was found. All results are from experiments conducted a
minimum of three times, and all graphs show Mean SEM.Author contributions
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